Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/15/2005CA2569279A1 Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors
12/15/2005CA2569277A1 Method for treating abnormal cell growth
12/15/2005CA2569266A1 Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
12/15/2005CA2569238A1 Monoamine reuptake inhibitor
12/15/2005CA2569234A1 Composition for treatment of a hydrofluoric acid burn
12/15/2005CA2569155A1 Formulations comprising a capsaicinoid a local anesthetic and/or an antipruritic agent for the treatment of pain
12/15/2005CA2569098A1 Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis
12/15/2005CA2568780A1 Hepoxilins and modulators of ichthyin for treatment skin disorders
12/15/2005CA2568773A1 Cis pyrrolidinyl derivatives and their uses
12/15/2005CA2568769A1 Trans pyrrolidinyl derivatives and their pharmaceutical use
12/15/2005CA2568750A1 Compositions and methods for treatment of neovascular diseases
12/15/2005CA2568718A1 Tetrahydropyridothiophenes for use in the treatment of cancer
12/15/2005CA2568671A1 Use of imatinib to treat liver disorders and viral infections
12/15/2005CA2568639A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
12/15/2005CA2568622A1 Dual small molecule inhibitors of cancer and angiogenesis
12/15/2005CA2568616A1 Partially-fluorinated ethers, compositions and uses thereof, for long-term tamponade in the eye
12/15/2005CA2568598A1 Systems and methods for treating panic attacks
12/15/2005CA2568524A1 Modulators of muscarinic receptors
12/15/2005CA2568523A1 Process to prepare camptothecin derivatives
12/15/2005CA2568501A1 Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
12/15/2005CA2568415A1 Novel saccharothrix strain and antibiotics derived therefrom, i.e. mutactimycins and aldgamycins
12/15/2005CA2568393A1 Methods for treating a mammal before, during and after cardiac arrest
12/15/2005CA2568341A1 Leptomycin compounds
12/15/2005CA2568249A1 Synthesis of metabolically stable analgesics, pain medications and other agents
12/15/2005CA2568218A1 Multiple agent therapy for sexual dysfunction
12/15/2005CA2568213A1 Composition and method for the treatment of tauopathies
12/15/2005CA2568165A1 Heterocyclic compounds and their use as aldosterone synthase inhibitors
12/15/2005CA2568164A1 Heterocyclic compounds and their use as aldosterone synthase inhibitors
12/15/2005CA2568163A1 Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors
12/15/2005CA2568159A1 Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors
12/15/2005CA2567909A1 Benzoxazolone derivatives, processes for preparing them and their uses
12/15/2005CA2567883A1 Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
12/15/2005CA2567852A1 Treatment with cisplatin and an egfr-inhibitor
12/15/2005CA2567838A1 Treatment of cancer in pediatric patients
12/15/2005CA2567836A1 Treatment with gemcitabine and an egfr-inhibitor
12/15/2005CA2567832A1 Quinazoline derivatives as erbb receptor tyrosine kinases
12/15/2005CA2567831A1 N-sulfonylcarboximidamide apoptosis promoters
12/15/2005CA2567803A1 Injectable pharmaceutical suspension comprising posaconazole
12/15/2005CA2567801A1 Diarylalkanes as potent inhibitors of binuclear enzymes
12/15/2005CA2567648A1 Novel tetrahydropyridothiophenes
12/15/2005CA2567495A1 Methods for treating bleeding disorders using sulfated polysaccharides
12/15/2005CA2567489A1 Pyridin-2-one compounds and their use as modulators of the dopamine d3 receptor
12/15/2005CA2567356A1 Magnesium complexes of s-omeprazole
12/15/2005CA2567289A1 Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
12/15/2005CA2567080A1 Ice inhibitors for the treatment of autoinflammatory diseases
12/15/2005CA2566974A1 Treatment with oxaliplatin and an egfr-inhibitor
12/15/2005CA2566971A1 Treatment with irinotecan (cpt-11) and an egfr-inhibitor
12/15/2005CA2566886A1 Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
12/15/2005CA2566811A1 Compositions and methods for treatment of premenstrual dysphoric disorder
12/15/2005CA2566594A1 Butyrylcholinesterase selective inhibitors
12/15/2005CA2566571A1 Treatment methods utilizing albumin-binding proteins as targets
12/15/2005CA2566531A1 Cycloalkyl substituted pyrimidinediamine compounds and their uses
12/15/2005CA2566518A1 Compositions and methods using same for treating neurodegenerative disorders
12/15/2005CA2566217A1 Pharmaceutical compositions for the treatment of pruritus
12/15/2005CA2566187A1 Mercaptoimidazoles as ccr2 receptor antagonists
12/15/2005CA2566161A1 Aryl ketone compounds and compositions for delivering active agents
12/15/2005CA2565968A1 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
12/15/2005CA2565689A1 Substituted pyrrolidine-2-ones
12/15/2005CA2565326A1 Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity
12/15/2005CA2565280A1 Mercaptoimidazoles as ccr2 receptor antagonists
12/15/2005CA2565159A1 Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
12/15/2005CA2563831A1 Monocyclic heterocycles as kinase inhibitors
12/15/2005CA2563699A1 Kinase modulators and method of use
12/15/2005CA2563697A1 Ozonized pharmaceutical composition and method
12/15/2005CA2563445A1 Compositions and methods for modulating vascular development
12/15/2005CA2562713A1 Phosphonate analogs of hiv integrase inhibitor compounds
12/15/2005CA2562332A1 Amino-propanol derivatives
12/15/2005CA2561858A1 Arylsulfonamides and uses related thereto
12/15/2005CA2561700A1 Combination of proton pump inhibitor, buffering agent, and prokinetic agent
12/15/2005CA2560984A1 Process for preparation of amorphous form of a drug
12/15/2005CA2510001A1 A process for the preparation of keto compounds
12/14/2005EP1605061A1 Neisseria genomic sequences and methods of their use
12/14/2005EP1605047A1 Chimeric and/or growth-restricted flaviviruses
12/14/2005EP1605043A1 Induction of methylation of cpg sequence by dsrna in mammalian cell
12/14/2005EP1604993A1 Inhibitors
12/14/2005EP1604992A1 Process for the preparation of 10alpha-[4'-(S-S-Dioxothothiomorpholin-1'-yl)]-10-Deoxo-10-Dihydroartemisinin
12/14/2005EP1604991A1 Antitumor effect potentiator and antitumor agent
12/14/2005EP1604990A1 Phenanthroindolizidine alkaloids
12/14/2005EP1604989A1 DPP-IV inhibitors
12/14/2005EP1604984A1 Water-soluble phenylpyridazine derivative and medicine containing the same
12/14/2005EP1604983A1 Receptor antagonist
12/14/2005EP1604982A1 Intermediates for the preparation of piperidine derivatives useful as modulators of chemokine receptor activity
12/14/2005EP1604980A1 DPP-IV inhibitors
12/14/2005EP1604979A1 2-oxo-1-pyrrolidine derivative and its pharmaceutical uses
12/14/2005EP1604971A1 Cinnamyl alcohol derivative compounds and drugs containing the compounds as the active ingredient
12/14/2005EP1604970A1 2-(Biphenyl-3-yl)-carboxylic acids of gamma-secretase-modulating activity
12/14/2005EP1604687A1 Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer
12/14/2005EP1604686A1 Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
12/14/2005EP1604683A2 Subcutaneously-administered ganglioside-based vaccine compositions
12/14/2005EP1604682A1 Gonadal function improving agents
12/14/2005EP1604671A1 Muscle-building agent and preventive or remedy for muscle weakening
12/14/2005EP1604670A1 Supplemental food for recovery from hypoglycemic symptoms
12/14/2005EP1604669A1 Use of ATP analogues for treatment of cardiovascular diseases
12/14/2005EP1604668A1 Hepoxilins and modulators of ichthyin for treating skin disorders
12/14/2005EP1604667A1 Opioids for the treatment of the restless leg syndrome
12/14/2005EP1604666A1 Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
12/14/2005EP1604665A1 C-kit kinase inhibitor
12/14/2005EP1604664A1 Medicine for prevention of and treatment for arteriosclerosis and hypertension
12/14/2005EP1604663A1 Zolpidem Hemitartrate Form H Solvate
12/14/2005EP1604662A1 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
1 ... 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 4453 4454 ... 7860